Based on all available data in cancer models and its physiological role in mammary epithelial proliferation in—as far as we know—every pregnant mammal, RANKL blockade could be a feasible option for the prevention of breast cancer in BRCA1-mutation carriers. This evidence concerns the gene TNFSF11 and cancer.